Search 7,500+ licensed pharmacies to find the best value, closest location, and fastest turnaround for
.
Finasteride inhibits 5-alpha reductase type II, blocking the conversion of testosterone to DHT (dihydrotestosterone) — the primary androgen responsible for follicle miniaturization in androgenetic alopecia. Topical application delivers the drug locally to the scalp with minimal systemic absorption.
No FDA-approved topical finasteride product exists. Compounding pharmacies create custom topical solutions and combinations (finasteride + minoxidil) that deliver scalp-targeted DHT inhibition with a fraction of the systemic exposure of oral Propecia — significantly reducing the side effect profile.
Compare up to 7,500 pharmacies across the USA.
Finasteride is a 5-alpha reductase inhibitor that blocks DHT synthesis — the primary driver of androgenetic alopecia (male pattern hair loss) and benign prostatic hyperplasia. Oral finasteride (Propecia, 1mg) is FDA-approved for hair loss but carries well-documented risks of sexual dysfunction, mood changes, and post-finasteride syndrome that deter many patients.
Topical finasteride achieves therapeutic DHT suppression in scalp tissue while limiting systemic DHT reduction by up to 90% compared to oral dosing. Clinical studies show topical finasteride produces comparable hair regrowth to oral finasteride with significantly reduced serum DHT suppression and side effect rates.
The most popular compounded formulation combines topical finasteride with minoxidil — addressing both DHT-mediated follicle miniaturization and blood flow/growth cycle simultaneously in a single daily application.
5-Alpha Reductase Inhibition (Type II)
Finasteride selectively inhibits 5-alpha reductase type II, the enzyme responsible for converting testosterone to DHT in hair follicles and the prostate. This reduces scalp DHT levels, allowing miniaturized follicles to recover and produce thicker terminal hairs.
Topical vs. Oral Systemic Exposure
Topical finasteride (0.1–0.25%) achieves local scalp DHT suppression comparable to oral 1mg while reducing serum DHT suppression by ~75–90%. This dramatically lowers the risk of systemic androgenic side effects including sexual dysfunction.
Male Pattern Baldness (AGA): Frontal recession, vertex thinning, diffuse androgenetic alopecia
Combination Therapy: Paired with topical minoxidil for synergistic, dual-mechanism hair loss treatment
Side Effect Sensitive Patients: Men who want finasteride's efficacy without oral systemic exposure
Topical finasteride solo (0.1–0.25%): 1mL applied to affected scalp once daily
Topical finasteride + minoxidil combination: 0.1–0.25% finasteride + 5% minoxidil applied once or twice daily
Results require 6–12 months of consistent daily use to assess. Hair loss resumes if treatment is stopped.
Significantly reduced vs. oral finasteride:
Important: Some systemic absorption still occurs — patients concerned about any systemic exposure should discuss with their provider.
Submit a quote request to find the lowest price. Quotes delivered to your inbox.
Find Lowest Price.png){kind=spacer}
